Semaglutide Complete Guide: Ozempic vs Wegovy, Dosing, Side Effects, and 2026 Research
Semaglutide has transformed the treatment of type 2 diabetes and obesity. Marketed as Ozempic for diabetes management and Wegovy for chronic weight management, this once-weekly injectable GLP-1 receptor agonist has become one of the most prescribed medications in the United States — and for good reason. Clinical trials show average body weight reductions of 15–21%, with robust cardiovascular benefits on top.
This guide covers everything you need to know: how semaglutide works, who qualifies, the full dosing protocol, what to expect from side effects, how it compares to tirzepatide, and what the latest 2025–2026 research reveals about long-term outcomes.
What Is Semaglutide?
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone released from the gut after eating. The drug was developed by Novo Nordisk and first approved by the FDA in 2017 for type 2 diabetes (as Ozempic). The higher-dose formulation for obesity (Wegovy) received FDA approval in 2021.
It exists in three forms:
- Ozempic (semaglutide injection 0.5 mg, 1 mg, 2 mg) — for type 2 diabetes and cardiovascular risk reduction
- Wegovy (semaglutide injection 2.4 mg) — for chronic weight management
- Rybelsus (oral semaglutide 3 mg, 7 mg, 14 mg) — for type 2 diabetes; an oral 25 mg Wegovy formulation launched in early 2026
How Semaglutide Works: Mechanism of Action
Semaglutide binds and activates GLP-1 receptors throughout the body. Its therapeutic effects stem from several simultaneous actions:
Appetite and Satiety Regulation
GLP-1 receptors in the hypothalamus and brainstem regulate hunger and fullness signals. Semaglutide activates these receptors to reduce appetite, enhance satiety, and decrease food cravings — particularly for high-fat, high-calorie foods. This central nervous system effect is responsible for the majority of the weight loss seen in clinical trials.
Gastric Emptying
Semaglutide slows the rate at which food moves from the stomach into the small intestine. This delays the rise in blood glucose after meals and prolongs feelings of fullness.
Glucose-Dependent Insulin Secretion
In people with type 2 diabetes, semaglutide stimulates insulin release from pancreatic beta cells when blood glucose is elevated. Crucially, this effect is glucose-dependent — it does not trigger insulin secretion at normal blood glucose levels, greatly reducing the risk of hypoglycemia compared to older diabetes medications.
Glucagon Suppression
Semaglutide suppresses glucagon, the hormone that tells the liver to release stored glucose. This further lowers blood sugar levels in people with diabetes.
FDA-Approved Indications and Who Qualifies
For Type 2 Diabetes (Ozempic)
Ozempic is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. It also carries a cardiovascular indication: reducing the risk of major adverse cardiovascular events (MACE — heart attack, stroke, and cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease.
For Chronic Weight Management (Wegovy)
Wegovy is indicated for long-term weight management in adults who meet at least one of these criteria:
- BMI ≥ 30 kg/m² (obesity)
- BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
In 2022, the FDA expanded the indication to include adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex. In 2024, Wegovy received an additional cardiovascular indication — the first weight-loss drug to reduce MACE risk — based on the landmark SELECT trial.
Semaglutide Dosing Protocol
Both Ozempic and Wegovy use a gradual dose escalation schedule designed to minimize gastrointestinal side effects while the body adjusts.
Wegovy (Weight Management) Titration
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg/week |
| 5–8 | 0.5 mg/week |
| 9–12 | 1.0 mg/week |
| 13–16 | 1.7 mg/week |
| 17+ | 2.4 mg/week (maintenance) |
If a patient cannot tolerate the step-up dose, the titration can be paused at the prior dose for an additional 4 weeks before attempting the increase again.
New Higher-Dose Option (2026)
In March 2026, the FDA approved semaglutide 7.2 mg/week following the STEP UP Phase 3b trial published in The Lancet Diabetes & Endocrinology. Patients on 7.2 mg lost an average of 20.7% of body weight over 72 weeks, compared to 17.5% on the standard 2.4 mg dose — a meaningful additional benefit for patients who need more.
Ozempic (Type 2 Diabetes) Dosing
For diabetes, the starting dose is 0.25 mg/week for 4 weeks (to allow GI adjustment), then increased to 0.5 mg/week. If further glycemic control is needed, doses can be escalated to 1 mg/week and then 2 mg/week at 4-week intervals.
Clinical Trial Evidence: The STEP Program
The STEP (Semaglutide Treatment Effect in People with Obesity) program is the most comprehensive clinical trial program ever conducted for a weight-loss medication. The pivotal STEP 1 trial enrolled 1,961 adults with obesity and reported results at 68 weeks:
- −14.9% average body weight reduction with semaglutide 2.4 mg vs. −2.4% with placebo
- 86.4% of participants achieved ≥5% weight loss
- 69.1% achieved ≥10% weight loss
- 50.5% achieved ≥15% weight loss
The STEP 5 trial demonstrated that these results were durable at 2 years, with sustained weight loss of approximately 15% body weight maintained through 104 weeks of treatment.
SELECT: The Cardiovascular Milestone
The SELECT trial enrolled 17,604 adults with established cardiovascular disease, overweight or obesity, but without diabetes. Results showed a 20% relative risk reduction in MACE with semaglutide versus placebo over approximately 3 years — making Wegovy the first obesity medication with proven cardiovascular benefit.
Side Effects: What to Expect
Common (Gastrointestinal)
GI effects are the most common side effects and typically occur during dose escalation:
- Nausea (up to 44% of patients in trials)
- Diarrhea (~30%)
- Vomiting (~25%)
- Constipation (~25%)
- Stomach pain and bloating
These effects usually subside within a few weeks as the body adapts. The gradual titration schedule is specifically designed to minimize GI discomfort.
Serious but Rare
- Pancreatitis — reported in clinical trials; semaglutide is contraindicated in patients with a history of pancreatitis
- Gallbladder disease — gallstones and acute cholecystitis have been reported, likely related to rapid weight loss
- Gastroparesis — prolonged gastric emptying delay; rare but increasingly reported in real-world use
- Bowel obstruction — rare but has been documented
Emerging Findings (2025–2026)
A 2025 Harvard/CDC analysis found that serious adverse events requiring emergency care occur in fewer than 4 per 1,000 patients annually — a reassuringly low rate. However, several newer signals are under investigation:
- A Swedish study (July 2025) found a possible association between semaglutide and retinal vein occlusion
- A Veterans Health Administration analysis found approximately double the rate of nonarteritic anterior ischemic optic neuropathy (NAION) in patients starting semaglutide — though absolute risk remains very low
- Animal data on the oral SNAC excipient and gut microbiome changes require human follow-up
Most experts consider the cardiovascular, metabolic, and weight-loss benefits to substantially outweigh these rare risks for most eligible patients.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Pregnancy or breastfeeding
- Prior pancreatitis (relative contraindication)
Semaglutide vs. Tirzepatide: Which Is Better?
Tirzepatide (Mounjaro/Zepbound) is the other major GLP-1 medication, adding GIP (glucose-dependent insulinotropic polypeptide) receptor agonism to GLP-1 activity. The two drugs are frequently compared — here's what the latest head-to-head evidence shows:
Weight Loss
Tirzepatide generally produces greater weight loss. The SURMOUNT-5 trial (the first direct head-to-head comparison in obesity) found tirzepatide 15 mg produced approximately 20.2% body weight reduction versus 13.7% for semaglutide 2.4 mg — a statistically significant advantage for tirzepatide. With the new semaglutide 7.2 mg dose, the gap narrows but tirzepatide at high doses still leads.
Cardiovascular Outcomes
The picture here is more nuanced:
- A 2025 real-world STEER study (ESC Congress) found semaglutide showed a 57% greater risk reduction in MACE vs. tirzepatide in patients with obesity and established cardiovascular disease without diabetes
- A SURMOUNT-5 post-hoc analysis suggested tirzepatide has an advantage in predicted 10-year CVD risk in primary prevention scenarios
- A Nature Medicine trial emulation (2025) found similar MACE outcomes between both drugs in patients with T2DM
Bottom line: For patients with established cardiovascular disease, semaglutide currently has stronger evidence. For maximum weight loss, tirzepatide holds a modest advantage.
Practical Differences
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Max weight loss (trials) | ~15–21% | ~20–22% |
| CV outcome trial | SELECT (proven) | SURMOUNT-MMO (ongoing) |
| Oral option available | Yes (Wegovy 25 mg, 2026) | No (as of April 2026) |
| Pediatric approval | Yes (≥12 yrs) | Yes (≥12 yrs, 2024) |
Long-Term Outcomes and Durability
One of the most important questions about semaglutide is what happens when patients stop taking it. The STEP 4 trial addressed this directly: patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their prior weight loss within 1 year. This underscores that semaglutide treats obesity as a chronic condition — most patients will need to continue treatment indefinitely to maintain results.
The good news: the STEP 5 trial confirmed that weight loss is well-maintained with continuous use out to 2 years. Emerging data from real-world cohorts suggest similar durability at 3+ years, though long-term studies are still accumulating.
Beyond weight, sustained treatment is associated with:
- Improved HbA1c and blood glucose control
- Reduced blood pressure
- Improved lipid profiles
- Reduced risk of sleep apnea symptoms
- Reduced MACE risk (SELECT)
Compounded Semaglutide: What You Need to Know
During the 2022–2024 period when FDA-approved semaglutide faced widespread shortages, compounding pharmacies began producing semaglutide at substantially lower cost. The FDA declared the shortage resolved in early 2025, and subsequently determined that most 503A and 503B compounding of semaglutide was no longer legally permissible.
As of 2026, compounded semaglutide occupies a legal gray area. Some 503A pharmacies continue to offer it for individualized patient needs (e.g., specific dose combinations), and the FDA has taken enforcement action against certain compounders. Anyone considering compounded semaglutide should verify pharmacy credentials through NABP (National Association of Boards of Pharmacy) accreditation and consult with a licensed prescriber.
Practical Considerations: Storage, Administration, and Cost
Storage
- Refrigerate at 36–46°F (2–8°C); do not freeze
- After first use, may be stored at room temperature (up to 77°F/25°C) for up to 56 days
- Protect from light
Administration
Semaglutide injection is administered subcutaneously once weekly, on the same day each week. Injection sites include the abdomen, upper thigh, or upper arm. Rotate sites to minimize injection site reactions.
Cost and Insurance
List price for Wegovy is approximately $1,349/month; Ozempic is approximately $935/month. Insurance coverage varies widely. Novo Nordisk offers a savings card (up to $500/month off for eligible commercially insured patients). Medicare Part D began covering Wegovy for cardiovascular indications in 2024, but coverage for obesity alone remains limited under Medicare.
Conclusion
Semaglutide represents a paradigm shift in how medicine treats both obesity and cardiovascular risk. With average weight losses of 15–21%, proven reduction in heart attack and stroke risk, and a well-characterized safety profile, it is one of the most impactful medications introduced in the past decade. The approval of higher-dose semaglutide (7.2 mg) and oral Wegovy in 2026 expands the options further.
For most eligible patients — those with obesity or overweight plus a related health condition — the benefit-to-risk ratio is strongly favorable. As with any medication, individualized discussions with a prescriber remain essential, particularly regarding the long-term commitment required and management of GI side effects during titration.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.